113 related articles for article (PubMed ID: 37990600)
1. A phase 1 trial of AP30663, a K
Yfanti C; Vestbjerg B; Van't Westende J; Edvardsson N; Monfort LM; Olesen MS; Bentzen BH; Grunnet M; Eveleens Maarse BC; Diness JG; Kemme MJB; Sørensen U; Moerland M; van Esdonk MJ; Klaassen ES; Gal P; Holst AG
Br J Clin Pharmacol; 2024 Apr; 90(4):1027-1035. PubMed ID: 37990600
[TBL] [Abstract][Full Text] [Related]
2. First Clinical Study with AP30663 - a K
Gal P; Klaassen ES; Bergmann KR; Saghari M; Burggraaf J; Kemme MJB; Sylvest C; Sørensen U; Bentzen BH; Grunnet M; Diness JG; Edvardsson N
Clin Transl Sci; 2020 Nov; 13(6):1336-1344. PubMed ID: 32725783
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the K
Holst AG; Tomcsányi J; Vestbjerg B; Grunnet M; Sørensen US; Diness JG; Bentzen BH; Edvardsson N; Hohnloser SH; Bhatt DL; Dorian P
Nat Med; 2024 Jan; 30(1):106-111. PubMed ID: 38092897
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Action of the KCa2-Negative Modulator AP30663, a Novel Compound in Development for Treatment of Atrial Fibrillation in Man.
Bentzen BH; Bomholtz SH; Simó-Vicens R; Folkersen L; Abildgaard L; Speerschneider T; Muthukumarasamy KM; Edvardsson N; Sørensen US; Grunnet M; Diness JG
Front Pharmacol; 2020; 11():610. PubMed ID: 32477117
[TBL] [Abstract][Full Text] [Related]
5. The K
Diness JG; Kirchhoff JE; Speerschneider T; Abildgaard L; Edvardsson N; Sørensen US; Grunnet M; Bentzen BH
Front Pharmacol; 2020; 11():159. PubMed ID: 32180722
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of K
Diness JG; Abildgaard L; Bomholtz SH; Skarsfeldt MA; Edvardsson N; Sørensen US; Grunnet M; Bentzen BH
Front Pharmacol; 2020; 11():749. PubMed ID: 32508659
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic-pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter.
Mao Z; Wheeler JJ; Townsend R; Gao Y; Kshirsagar S; Keirns JJ
J Pharmacokinet Pharmacodyn; 2011 Oct; 38(5):541-62. PubMed ID: 21786177
[TBL] [Abstract][Full Text] [Related]
8. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
[TBL] [Abstract][Full Text] [Related]
9. Effects of azimilide on heart rate and ECG conduction intervals during sinus rhythm in patients with a history of atrial fibrillation.
Pritchett EL; Schulte MC; Schnell D; Marcello SR; Wilkinson WE; Page RL; Connolly SJ;
J Clin Pharmacol; 2002 Apr; 42(4):388-94. PubMed ID: 11936563
[TBL] [Abstract][Full Text] [Related]
10. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
11. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
12. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
Crijns HJ; Van Gelder IC; Walfridsson H; Kulakowski P; Rónaszéki A; Dedek V; Malm A; Almgren O
Heart Rhythm; 2006 Nov; 3(11):1321-31. PubMed ID: 17074639
[TBL] [Abstract][Full Text] [Related]
13. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
[TBL] [Abstract][Full Text] [Related]
14. Randomized study of the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval in healthy subjects.
Funck-Brentano C; Felices M; Le Fur N; Dubourdieu C; Desché P; Vanhoutte F; Voiriot P
Br J Clin Pharmacol; 2020 Nov; 86(11):2174-2181. PubMed ID: 32302009
[TBL] [Abstract][Full Text] [Related]
15. COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm.
Dittrich HC; Feld GK; Bahnson TD; Camm AJ; Golitsyn S; Katz A; Koontz JI; Kowey PR; Waldo AL; Brown AM
Heart Rhythm; 2015 Jun; 12(6):1105-12. PubMed ID: 25684233
[TBL] [Abstract][Full Text] [Related]
16. Absence of QTc Prolongation with Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC), an Absorption Enhancer Co-Formulated with the GLP-1 Analogue Semaglutide for Oral Administration.
Granhall C; Bækdal TA; Breitschaft A; Søndergaard FL; Anderson TW; Thomsen M
Diabetes Ther; 2021 Sep; 12(9):2599-2610. PubMed ID: 34319564
[TBL] [Abstract][Full Text] [Related]
17. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
18. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.
Hornestam B; Jerling M; Karlsson MO; Held P;
Eur J Clin Pharmacol; 2003 Mar; 58(11):747-55. PubMed ID: 12634981
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously.
Rónaszéki A; Alings M; Egstrup K; Gaciong Z; Hranai M; Király C; Sereg M; Figatowski W; Bondarov P; Johansson S; Frison L; Edvardsson N; Berggren A
Europace; 2011 Aug; 13(8):1148-56. PubMed ID: 21561900
[TBL] [Abstract][Full Text] [Related]
20. Inverse Correlation between the Atrial Fibrillatory Rate and the Ventricular Repolarization Time: Observations at Baseline and after an Intravenous Infusion of a Combined Potassium and Sodium Current Blocker.
Edvardsson N; Aunes M; Frison L; Berggren AR
Ann Noninvasive Electrocardiol; 2016 May; 21(3):236-45. PubMed ID: 26246430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
